BETHLEHEM

Embassy Bancorp, Inc. Announces Results of Operations as of and for the Three Months ended March 31, 2024

Retrieved on: 
Friday, May 17, 2024
OTCQX, File, Form 10-Q, Bank, Cryptocurrency

Cash and cash equivalents on hand of $59.5 million at March 31, 2024, or 3.6% of total assets.

Key Points: 
  • Cash and cash equivalents on hand of $59.5 million at March 31, 2024, or 3.6% of total assets.
  • The Company had no short or long term borrowings as of March 31, 2024, and during the three months ended March 31, 2024, repaid short-term borrowings of $35 million.
  • There were no new short or long term borrowings during the three months ended March 31, 2024.
  • Net income of $2.5 million, or $0.33 per diluted share, for the three months ended March 31, 2024.

Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test

Retrieved on: 
Tuesday, May 14, 2024
Patient, TDM, Toxicity, BSA, Oncology, Sale, Death, Health Canada, Frustration, European, Pharmaceutical industry

There is increasing concern with 5-FU treatments worldwide because some patients suffer severe toxicities and even death, which may have been avoided.

Key Points: 
  • There is increasing concern with 5-FU treatments worldwide because some patients suffer severe toxicities and even death, which may have been avoided.
  • There is growing frustration in the medical community with oncologists who are reticent to adopt the recommended guidelines for 5-FU TDM.
  • BSA dosing does not account for individual differences between patients, nor does it measure the blood level of the drug in the patient.
  • The Saladax My5-FU blood test, used in multiple countries worldwide, is now approved in Canada, the European Union, China, the United Kingdom, and Israel.

OraSure Reports Q1 ’24 Revenue of $54.1 Million

Retrieved on: 
Wednesday, May 8, 2024

BETHLEHEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2024.

Key Points: 

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

Retrieved on: 
Monday, April 22, 2024
OraSure Technologies, Webcast

BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m.

Key Points: 
  • BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m.
  • ET on Wednesday, May 8, 2024.
  • A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations .
  • Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call.

OraSure Reports Q4 ‘23 Revenue of $75.9 Million

Retrieved on: 
Tuesday, February 27, 2024

BETHLEHEM, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services, today announced its financial results for the three months ended December 31, 2023.

Key Points: 

The Wetrich Group Announces Executive Leadership Transitions

Retrieved on: 
Wednesday, February 14, 2024
PCC, BSN, Building, Growth, IDN, ICF, National accounts, RPC, GPO, Management

Southlake, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Wetrich Group LLC, a comprehensive advisory and consulting firm focused on the health care industry, has announced the appointment of Carl Meyer as President, who will succeed James G. Wetrich, effective immediately.

Key Points: 
  • Southlake, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Wetrich Group LLC, a comprehensive advisory and consulting firm focused on the health care industry, has announced the appointment of Carl Meyer as President, who will succeed James G. Wetrich, effective immediately.
  • Meyer joined The Wetrich Group in 2013, and most recently served as Executive Vice President.
  • While at BSN, he assisted the organization's transition from a direct supply chain to a distribution centric and group purchasing aligned organization.
  • Following his departure from The Wetrich Group, Wetrich will transition to a CEO Mentor role with Building Champions, a professional training and coaching organization headquartered in Lake Oswego, Oregon.

OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th

Retrieved on: 
Tuesday, February 13, 2024
OraSure Technologies, Webcast

BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certain business developments for 5 p.m.

Key Points: 
  • BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certain business developments for 5 p.m.
  • A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations .
  • Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call.
  • The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately 90 days.

OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company 

Retrieved on: 
Thursday, January 4, 2024
Partnership, Health, KKR, Electronics, OraSure Technologies, Series, Webcast, Global health, Computational biology, Pharmaceutical industry

BETHLEHEM, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced it is leading the Series B financing and has entered wide-ranging strategic distribution agreements with Sapphiros, a privately held consumer diagnostics portfolio company based in Boston, and certain of its related entities. Sapphiros was conceived in 2020 by experienced healthcare executive Namal Nawana and launched along with leading global investment firm KKR in 2021. The company has since developed innovative capabilities including novel sample collection, next-generation detection systems, computational biology, and printed electronics to help consumers access diagnostic results.

Key Points: 
  • Distribution of Sapphiros’ products is expected to accelerate OraSure’s core revenue growth rate beginning in 2025.
  • Sapphiros was conceived in 2020 by experienced healthcare executive Namal Nawana and launched along with leading global investment firm KKR in 2021.
  • The company has since developed innovative capabilities including novel sample collection, next-generation detection systems, computational biology, and printed electronics to help consumers access diagnostic results.
  • Through this strategic relationship, OraSure expects to be able to offer a more comprehensive range of low-cost diagnostic tests and sample management solutions to its customers globally.

Embassy Bancorp, Inc. Announces Results of Operations as of and for the Three and Nine Months ended September 30, 2023

Retrieved on: 
Thursday, November 16, 2023
OTCQX, Bank, File, Cryptocurrency

Cash and cash equivalents on hand of $77.7 million at September 30, 2023, or 4.6% of total assets.

Key Points: 
  • Cash and cash equivalents on hand of $77.7 million at September 30, 2023, or 4.6% of total assets.
  • Deposits of $1.472 billion at September 30, 2023, with non-interest bearing deposits of $320.7 million.
  • Bank assets per employee of $15.7 million at September 30, 2023, compared to the Pennsylvania peer group assets per employee of $6.5 million.
  • Net income of $9.8 million, or $1.29 per diluted share, for the nine months ended September 30, 2023.

OraSure to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, November 13, 2023
Q&A, OraSure Technologies, Conference

BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences:

Key Points: 
  • BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences:
    Stephens Annual Investment Conference on Wednesday, November 15, with a Q&A session scheduled for 2 p.m.
  • ET
    Evercore ISI Annual HealthCONx Conference on Tuesday, November 28, with a Q&A session scheduled for 3 p.m.
  • ET
    Live webcasts and replays of the sessions will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations .
  • The webcasts will be archived on OraSure’s website and will be available for approximately 90 days.